Document 2123
 DOCN  M94A2123
 TI    HIV/AIDS in Sweden. Health and medical care estimates with respect to
       CD4 levels and survival.
 DT    9412
 AU    Malmquist H; Nilsson BR; National Swedish Board of Health and Welfare,
       Stockholm.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):376 (abstract no. PD0110). Unique
       Identifier : AIDSLINE ICA10/94370452
 AB    OBJECT. The aim for this study was to give estimates on somatic care for
       HIV infected patients in Sweden. METHOD. Survival data on HIV positive
       patients (n = 2,253) was gathered from Danderyd and Huddinge university
       hospitals. Stockholm, stratified on CD4 values < = 200, 201-300 and
       301-500 units. Survival times for patients within these strata were
       calculated by the life table method. Median survival times were then
       used to calculate mean expected costs for the patients within the
       different CD4-group. Knowing the distribution of patients on stage and
       costs per patient on stage we were able to give cost estimates for
       somatic care for the Swedish HIV population with CD4-count below 500
       units for the rest of the life for the patients. RESULTS. The mean
       expected survival time for a HIV patient with a CD4 value below 500
       units was estimated to be 4.7 years. The distribution of HIV infected
       persons was assumed to be the same for the total known Swedish HIV
       population as for the Danderyd/Huddinge cohort. Of 2,519 known HIV
       infected persons in Sweden (Jan 1993) 1,887 (75%) could be estimated to
       have CD4-counts below 500 units. The expected number of person years
       (py) until death for these patients would than be 4.7 years x 1,887
       patients = 8,878 py. The total costs for this population is estimated to
       be 1.2 billion SEK, i.e. 154 million USD. CONCLUSION. By combinating the
       number of HIV patients by CD4 level and costs per py as estimated by
       median survival times it was possible to calculate estimates on costs
       for medical care for cohorts of patients in Sweden.
 DE    Acquired Immunodeficiency Syndrome/*ECONOMICS/IMMUNOLOGY/  MORTALITY
       Cohort Studies  Comprehensive Health Care/*ECONOMICS  Costs and Cost
       Analysis  Human  HIV Infections/*ECONOMICS/IMMUNOLOGY/MORTALITY
       Leukocyte Count  Life Expectancy  Survival Rate  Sweden  T4
       Lymphocytes/IMMUNOLOGY  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).